Cycle Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CYCLE, and when can generic versions of CYCLE drugs launch?
CYCLE has thirteen approved drugs.
There are four US patents protecting CYCLE drugs.
There are sixteen patent family members on CYCLE drugs in eighteen countries and twenty-four supplementary protection certificates in thirteen countries.
Summary for Cycle
| International Patents: | 16 |
| US Patents: | 4 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 13 |
Drugs and US Patents for Cycle
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle | PIROXICAM | piroxicam | CAPSULE;ORAL | 073651-001 | Feb 26, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-001 | Dec 23, 2021 | RX | Yes | No | 10,555,902 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cycle | INDOMETHACIN | indomethacin | CAPSULE;ORAL | 070354-001 | Jun 18, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Cycle | QUINIDINE SULFATE | quinidine sulfate | TABLET;ORAL | 085632-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-001 | Dec 23, 2021 | RX | Yes | No | 9,925,138 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Cycle | TASCENSO ODT | fingolimod lauryl sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 214962-002 | Dec 9, 2022 | RX | Yes | Yes | 10,555,902 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cycle | NITYR | nitisinone | TABLET;ORAL | 209449-001 | Jul 26, 2017 | RX | Yes | No | 10,328,029 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cycle Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Cyprus | 1123394 | ⤷ Try a Trial |
| Spain | 2806739 | ⤷ Try a Trial |
| United Kingdom | 201400117 | ⤷ Try a Trial |
| Hungary | E050881 | ⤷ Try a Trial |
| Portugal | 3089740 | ⤷ Try a Trial |
| Taiwan | 201642842 | ⤷ Try a Trial |
| Canada | 2974375 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cycle Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0627406 | 11C0021 | France | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMOD ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES EN PARTICULIER SON CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/11/677/001 20110317 |
| 1613288 | C20110013 00043 | Estonia | ⤷ Try a Trial | PRODUCT NAME: GILENYA - FINGOLIMOD; REG NO/DATE: FINAL 17.03.2011 |
| 0627406 | SPC/GB11/026 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317 |
| 1613288 | PA2011010 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011 03 17 EU/1/11/677/002, 2011 03 17 EU/1/11/677/003, 2011 03 17 EU/1/11/677/004 20110317 |
| 1613288 | SPC/GB11/045 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317 |
| 1613288 | 2011C/030 | Belgium | ⤷ Try a Trial | PRODUCT NAME: FINGOLIMOD; AUTHORISATION NUMBER AND DATE: EU/1/11/677/001 20110322 |
| 0591275 | SPC/GB05/030 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
